GlassScriptPhysician profile
Michael J Keller
NPI 1013164086
$9,461.12
in general payments reported to CMS, 2019-2025
33 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $580 · 2021: $951 · 2022: $2,830 · 2023: $2,102 · 2024: $1,251 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $2,272.64 | 2019-2025 | Remodulin, Tyvaso, Orenitram |
| Glaxosmithkline, LLC. | $2,109.14 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $842.74 | 2019-2024 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $783.99 | 2019-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $655.74 | 2019-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $369.32 | 2019-2024 | |
| Electromed, INC. | $214.81 | 2019-2024 | Smartvest |
| Janssen Pharmaceuticals, INC | $210.32 | 2019-2024 | Opsumit, Uptravi |
| Mallinckrodt Hospital Products INC. | $205.90 | 2021-2023 | Acthar |
| Mylan Specialty L.P. | $181.42 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $180.61 | 2019-2022 | |
| Grifols USA, LLC | $164.29 | 2019-2023 | Prolastin-C Liquid |
| Genentech USA, INC. | $147.34 | 2019-2020 | |
| Harmony Biosciences LLC | $128.92 | 2023 | Wakix |
| Pfizer INC. | $115.85 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $98.15 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.55 | 2023-2024 | Glassia |
| Sunovion Pharmaceuticals INC. | $85.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $85.53 | 2023-2025 | Dupixent |
| Baxter Healthcare | $82.85 | 2021-2024 | Hillrom - Vest System Model 105 Home Care |
| Intuitive Surgical, INC. | $80.54 | 2023 | Da Vinci Surgical System |
| Philips North America LLC | $61.17 | 2021-2024 | (Ak6) Vest Therapy |
| Shionogi INC | $57.16 | 2023 | Fetroja |
| Merck Sharp & Dohme LLC | $52.92 | 2019-2024 | Recarbrio, Dificid, Zerbaxa |
| Teva Pharmaceuticals USA, INC. | $40.24 | 2019-2021 | |
| Sandoz INC. | $30.40 | 2019-2020 | |
| Amgen INC. | $27.61 | 2022 | |
| Advanced Respiratory, INC | $23.53 | 2019 | |
| Vapotherm INC | $15.40 | 2021 | |
| Mayne Pharma Commercial LLC | $15.25 | 2019 | |
| Itamar Medical INC | $13.54 | 2023 | Watchpatone |
| Bausch Health US, LLC | $13.09 | 2019 | |
| Inogen, INC. | $6.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.